R&D Efficiency: Big Pharma Overview

Explore R&D investment and innovation output across leading pharmaceutical companies through an interactive data visualizer.

R&D Efficiency: Big Pharma Overview

Explore R&D investment and innovation output across leading pharmaceutical companies through an interactive data visualizer.
Cyntegrity logo – Risk-Based Quality Management Solutions

Understanding R&D Efficiency Through Data

The eyesON R&D Efficiency: Big Pharma Overview visualizer presents a clear, data-focused view of how R&D spending translates into regulatory outcomes across major publicly traded pharmaceutical companies.

By connecting R&D investment levels with FDA-approved New Molecular Entities (NMEs) and Biologic License Applications (BLAs), the tool illustrates how efficiently organizations convert research spending into approved innovation. The result is a comparative view of R&D Return on Investment (ROI) across the industry.

Rather than relying on static tables or isolated metrics, the visualizer allows users to explore the relationship between strategic investment and regulatory success in a single interactive environment.

What You Can Do With the Visualizer

The visualizer supports analysis of pharmaceutical innovation performance at a company level.

R&D Spend vs. Regulatory Output

See how R&D expenditures relate to the number of FDA-approved NMEs and BLAs across leading pharma companies.

Company-Level Innovation Profiles

Explore how individual organizations perform in terms of R&D efficiency and regulatory productivity.

ROI-Oriented Insights

Understand differences in R&D return by visualizing investment patterns alongside approval outcomes.

Designed for Insight, Not Just Numbers

The eyesON R&D Efficiency visualizer is built to reveal patterns behind innovation performance. By presenting data visually, it helps users move beyond raw figures and see how investment strategies align with regulatory achievements across the industry.

It is equally relevant for professionals refining R&D decision-making and for anyone interested in understanding how large pharmaceutical organizations translate research budgets into approved therapies.

Where Do the Data and Methods Come From?
The visualizer uses publicly available financial data from sec.gov and gurufocus.com, combined with FDA approval data for NMEs and BLAs from fda.gov. More details on data sources, extraction methods, and the analytical approach are available in the Data Definition tab within the app.

Part of the eyesON Interactive Visualizer Series

R&D Efficiency: Big Pharma Overview is part of eyesON, a series of free interactive data visualizers developed by Cyntegrity. The eyesON series reflects Cyntegrity’s commitment to sharing data analytics capabilities and clinical research expertise with the wider research community. Each visualizer is designed to make complex industry data easier to explore, compare, and apply in real-world decision-making.

Interested in exploring more interactive data visualizers from Cyntegrity? You can discover the full eyesON collection through the platform. Explore More Interactive Visualizers…

Explore Our Visualizer

See how other datasets can sharpen signal awareness and decision-making.

Stay Informed with Us

RBQM explained: transition from 100% SDV to risk-based monitoring and centralized oversight

RBQM Explained: Why 100% SDV Falls Short in Clinical Trials

An educational excerpt from MyRBQM Essentials White Belt explaining why traditional monitoring and 100% Source Data Verification are no longer enough for modern clinical trial oversight....

Protocol Complexity and RBQM in Clinical Trials

New research shows protocol complexity continues to increase. Learn why Risk-Based Quality Management and AI-supported oversight are becoming essential....

Media Inquiries

Need a quote, speaker, or more info about Cyntegrity? Reach out directly to our media contact for timely assistance.

What Is the Financial Value of RBQM?

Download the updated case study with 2026 Tufts CSDD insights
and Cyntegrity’s operational value perspective.